Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -8.03% is 74% above its 5-year average of -30.50%, near the high end of its 5-year range (-62.78%–-8.03%).
As of the fiscal period ended Tuesday, June 30, 2026. 26.50% above its 12-month average of -10.92%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -8.03%.
RETURN ON EQUITY (ROE)
-8.03%
RETURN ON EQUITY (ROE) AVG TTM
-10.92%
RETURN ON EQUITY (ROE) AVG 3Y
-18.46%
RETURN ON EQUITY (ROE) AVG 5Y
-30.50%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+26.50%
CURRENT VS 3Y AVG
+56.53%
CURRENT VS 5Y AVG
+73.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+80.89%
vs the sector median at left
SI-BONE, Inc.
Market Cap
$867.03M
Return on Equity (ROE)
-8.03%
TTM Avg
-10.92%
3Y Avg
-18.46%
5Y Avg
-30.50%
Market Cap
$870.81M
Return on Equity (ROE)
N/A
TTM Avg
30.44%
3Y Avg
30.44%
5Y Avg
30.44%
Market Cap
$857.16M
Return on Equity (ROE)
-59.07%
TTM Avg
-63.84%
3Y Avg
-29.19%
5Y Avg
-3.25%
Market Cap
$855.38M
Return on Equity (ROE)
-97.08%
TTM Avg
-96.94%
3Y Avg
-22.72%
5Y Avg
-22.72%
Market Cap
$853.13M
Return on Equity (ROE)
75.67%
TTM Avg
312.76%
3Y Avg
285.83%
5Y Avg
166.15%
Market Cap
$852.35M
Return on Equity (ROE)
-167.25%
TTM Avg
-94.03%
3Y Avg
-58.96%
5Y Avg
-58.96%
Market Cap
$884.97M
Return on Equity (ROE)
59.16%
TTM Avg
-57.78%
3Y Avg
-58.75%
5Y Avg
-57.09%
Market Cap
$887.50M
Return on Equity (ROE)
23.86%
TTM Avg
-5.16%
3Y Avg
-37.28%
5Y Avg
-22.23%
Market Cap
$887.99M
Return on Equity (ROE)
-24.02%
TTM Avg
-108.12%
3Y Avg
-89.93%
5Y Avg
-68.76%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SI-BONE, Inc. (SIBN) | $867.03M | -8.03% | -10.92% | -18.46% | -30.50% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $870.81M | N/A | 30.44% | 30.44% | 30.44% |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | -59.07% | -63.84% | -29.19% | -3.25% |
| Alumis Inc. (ALMS)vs › | $855.38M | -97.08% | -96.94% | -22.72% | -22.72% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 75.67% | 312.76% | 285.83% | 166.15% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | -167.25% | -94.03% | -58.96% | -58.96% |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | 59.16% | -57.78% | -58.75% | -57.09% |
| Bioventus Inc. (BVS)vs › | $887.50M | 23.86% | -5.16% | -37.28% | -22.23% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | -24.02% | -108.12% | -89.93% | -68.76% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | N/A | -5137.85% | -2593.82% | -1731.57% |
ROE
-8.0%
ROA
-5.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -8.03% |
| 2026-03-31 | -9.33% |
| 2025-12-31 | -10.65% |
| 2025-09-30 | -12.64% |
| 2025-06-30 | -13.95% |
| 2025-03-31 | -15.87% |
| 2024-12-31 | -18.51% |
| 2024-09-30 | -22.67% |
| 2024-06-30 | -24.80% |
| 2024-03-31 | -26.05% |
| 2023-12-31 | -25.59% |
| 2023-09-30 | -25.07% |
| 2023-06-30 | -26.87% |
| 2023-03-31 | -58.51% |
| 2022-12-31 | -62.31% |
| 2022-09-30 | -62.78% |
| 2022-06-30 | -59.79% |
| 2022-03-31 | -50.43% |
| 2021-12-31 | -42.09% |
| 2021-09-30 | -35.56% |
| 2021-06-30 | -28.97% |
| 2021-03-31 | -26.70% |
| 2020-12-31 | -25.80% |
| 2020-09-30 | -42.94% |
| 2020-06-30 | -42.32% |
| 2020-03-31 | -35.98% |
| 2019-12-31 | -60.95% |
| 2019-09-30 | -50.20% |
| 2019-06-30 | -36.15% |
| 2019-03-31 | -27.30% |
| 2018-12-31 | -19.35% |
